Peroxisome proliferator-activated receptors as new molecular targets in psoriasis.
While psoriasis is upon the age of biological treatments, additional researches have led to other new therapies for psoriasis, including targets aimed at nuclear receptors. PPARs are members of the nuclear-hormone-receptor superfamily, including retinoid receptors and vitamin D receptors. Recent works have highlighted the role of PPARs, which transduce a wide variety of signals into a set of cellular responses at the level of gene transcription, as critical regulators of cutaneous homeostasis in regulating differentiation, proliferation, and inflammatory responses of the skin. PPAR agonists or antagonists may therefore, hold promise as interesting compounds for the treatment of various epidermal disorders characterized by inflammation, hyperproliferation and aberrant differentiation, such as psoriasis.
Kuenzli
Stephane
S
Department of Dermatology, University Hospital, Geneva, Switzerland. stephane.kuenzli@medecine.unige.ch
Saurat
Jean-Hilaire
JH
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D011565:Psoriasis / Q000378:metabolism* / Q000473:pathology; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism*
D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors